VERAXA Biotech
PrivateLast Round
M&A
Apr 22, 2025
Est. Valuation
$1.64B
Total Funding Raised
$3.41M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
VERAXA Biotech is a biotechnology company developing next-generation antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and T-cell engagers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VERAXA Biotech Comparables
Compare VERAXA Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CytomX Therapeutics | 87% | |
| Eli Lilly and Company | 79% | |
| Zymeworks Inc. | 78% | |
VERAXA Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Apr 22, 2025 | ||||
| Series B | Jun 27, 2019 |
VERAXA Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EMBLEM Technology Transfer | M&A, Series B |
| European Molecular Biology Laboratory | M&A, Series B |
| Xlife Sciences AG | M&A, Series B |
| Voyager Acquisition Corp. | M&A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 13, 2026
Open roles increased to 13, 5.2x the trailing average.
- Jan 19, 2026
Monthly visitors increased 34% MoM, reaching 3.1K.
VERAXA Biotech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VERAXA Biotech's valuation, stock price, and market status.